April 03, 2020 EUROoCS
After the presentation of the final results of the ORCHID project in Brussels during the FET seminar beginning of this year, managing director of hDMT Janny van den Eijnden-van Raaij was interviewed by the European Commission. In the article, she tells about the lack of models that mimic the human body for drug development, and how Organ-on-Chip technology can provide a solution for this deficit. The EU FET-Open project ORCHID, initiated by the Dutch Organ-on-Chip consortium hDMT, aimed to help Organs-on-Chips to move from the laboratory into real-life medical care.
Organ-on-Chip, as an emerging technology, could bridge the gap between preclinical testing and human trials through better predictive models and better safety profiles, significantly impacting the research and development costs. This can be beneficial for healthcare systems and pharmaceutical companies. Besides the pharmaceutical industry, Organ-on-Chip technology is of interest for:
•the food industry (for testing the allergenic potential of food ingredients)
•the cosmetic industry (for testing cosmetic products in particular because of the ban on animal use for skin and eye tests in Europe)
•the chemical industry (for testing hazardous effects of chemicals)
•the veterinary industry (for testing household pet medications and medical treatments)
Even the defense industry and government agencies are interested in Organ-on-Chip models for the assessments of threats from biological or chemical weapons and for safety assessment of environmental compounds.
A unique outcome of ORCHID is the foundation of a European community on Organ-on-Chip technology. This is the first sustainable (not finance-driven) infrastructure for Organ-on-Chip technology established to date.
Though the Organ-on-Chip field is still in its infancy, there are several examples of Organ-on-Chip models that showcase the potential of this technology. These examples include among others detection of thrombotic risk in Vessels-on-Chip, discovery of targets for metastases in Cancer-on-Chip, test for kidney toxicity in Kidney-on-Chip, drug effects on Neurons and Glia cells-on-Chip, prediction of toxicity of nanoparticles in Lung-on-Chip and drug discovery in a disease model for Amyotrophic Lateral Sclerosis (ALS).
The models still need to be properly qualified for their technological and biological performance, and their robustness and reproducibility demonstrated for a specific purpose. Since qualification, but also standardization, production and upscaling will accelerate the adoption of Organ-on-Chip technology, activities in this direction have the highest priority and have already been started. EUROoCS will initiate and catalyze these challenging processes.
Read the full success story of this breakthrough innovation at the website of the European Commission.
The Final Report in the form of a third ORCHID brochure describes the achievements of ORCHID and refers to the relevant documents that have been delivered during the 2-year ORCHID project.
ORCHID was selected for funding by FET Open Coordination and Support Actions (CSA) in 2017. FET Open and FET Proactive are now part of the Enhanced European Innovation Council (EIC) Pilot (specifically the Pathfinder), the new home for deep-tech research and innovation in Horizon 2020, the EU funding programme for research and innovation.
Sharing knowledge: the latest news
Travel Awards JRC Summer School on Non-animal Approaches in Science
EUROoCS will sponsor travel awards for two PhD students that are planning to…
Call for the organization of the Annual EUROoCS Conference
Next year, the 5th edition of the Annual EUROoCS Conference, EUROoCS 2024, will…
Membership fee 2023 payment
All members of EUROoCS have received their membership invoice for 2023, on February…
MPS World Summit 2023 abstract submission extended
The 2nd MPS world summit 2023 in Berlin is less than 6 months away.…
Would you like to become an active member of EUROoCS Working Groups?
EUROoCS has several Working Groups (WGs) for which we are looking for enthusiastic…
FDA Modernization Act 2.0 passes U.S. Senate
On Thursday, September 29, 2022 Senate Bill 5002, ‘FDA Modernization Act 2.0’ was both…
The EPAA European Partnership for Alternatives (EPAA3Rs) 2022 3Rs Science Prize is open for submissions.
The 3Rs science prize is granted every two years to a scientist with…
International 3Rs Prize winner
Congratulations to Dr Daniel Ferreira at the Instituto de Investigação e Inovação em…
Looking back at a succesful EUROoCS Conference 2022
The conference was a great success, a record number of participants, a very…
EUROoCS RAB presents resources for Organ-on-Chip validation and qualification at the EUROoCS 2022 Conference
The Regulatory Advisory Board (RAB) of EUROoCS is supporting activities in relation to…